About us

Pioneering Extrahepatic RNA delivery

Starna Therapeutics was founded in August 2021, focusing on extrahepatic targeted delivery technology. The company is dedicated to developing innovative RNA-based drugs to address unmet clinical needs. With the expertise in nucleic acid drug discovery, delivery technology, and process development, we have established a robust industrial chain encompassing chemistry, mRNA, and LNP preparations.

Leveraging our propretary STAR(Selective Targeted RNA Delivery) LNP technology platform, we are capable of delivering a diverse range of RNA-based modalities to specific organs and tissues, and more importantly, to individual cell types, like T cells. This comprehensive approach enables us to accurtely target delivery medicines and overcome the core challenges in RNA drug research and development.